Refine by
Bladder Cancer Suppliers & Manufacturers
32 companies found
based inCham, SWITZERLAND
The global healthcare system is fundamentally changing - advances in technology such as robotics and artificial intelligence as well as rising consumer expectations are driving a global shift in the healthcare landscape. Similarly to the ...
The Combat BRS System is an innovative bladder recirculation system designed to deliver. Combat BRS is an innovative bladder recirculation system for the treatment of non muscle invasive bladder carcinomas (NMIBC) with thermotherapy and cytostatic ...
based inSalt Lake City, UTAH (USA)
PYREXAR Medical is the pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established global distribution. PYREXAR Hyperthermia treatments increase the ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder ...
based inIrvine, CALIFORNIA (USA)
Established in 2011, Pathnostics is driven to pioneer a better future for physicians, patients, and the healthcare system with solutions that transform diagnostic and therapeutic dilemmas. Core capabilities in infectious disease and cancer ...
based inSan Francisco, CAMBODIA
Verana Health is a digital health company that delivers quality drug lifecycle, medical practice, and medical society insights from an exclusive real-world data network of more than 20,000 healthcare providers. Our specialty medical society partners ...
Verana Health’s exclusive real-world data network and clinically true Qdata™ can help accelerate clinical trials in ophthalmology, urology, and neurology—from study startup through recruitment. From protocol development and ...
based inAuburndale, MASSACHUSETTS (USA)
Imagin Medical, a surgical imaging company, is focusing on bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common cancer in men. It is the most expensive form of cancer to treat over the lifetime of a patient because ...
Introduced in 2010, blue light cystoscopy, uses blue-filtered white light to address the limitations of white light cystoscopy. This method involves administering a contrast agent into the bladder which is absorbed by the ...
based inParis, FRANCE
Oncovita is a biotech company developing a disruptive virus-derived vaccine technology to treat multiple types of cancers. Our MeasovirTM platform was developed based on the safe and highly immunogenic measles virus vaccine, a vaccine with ...
based inDurham, NORTH CAROLINA (USA)
GeneCentric Therapeutics is applying our proprietary rT(I)ME Explorer Platform to identify high resolution molecular subtypes and drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our ...
Bladder cancer is one of the most common types of cancer which like lung and other cancers, is quite heterogeneous. Bladder cancer occurs more ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of ...
based inPrinceton, NEW YORK (USA)
We are a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers. Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel ...
UroGen is developing UGN-102 (mitomycin) for intravesical solution as a primary nonsurgical alternative to repetitive TURBT. UGN-102 is an investigational formulation that utilizes our innovative technology, RTGel™ reverse-thermal hydrogel, ...
based inSan Diego, CALIFORNIA (USA)
Decipher, a part of Veracyte, offers genomic tests for urologic cancers. Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with ...
Decipher Bladder is the only genomic subtyping tool available to physicians in the United States treating patients with locally advanced bladder ...
based inGuangzhou, CHINA
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy ...
Cancer is a complicated disease caused by genetic variation. The genetic variation may deprive cells of the normal control function, leading to immortalization and cancer. And targeted drugs work well in cancer therapy, which can kill cancer cells ...
based inScottsdale, ARIZONA (USA)
Tesis Biosciences’ unique integrated medical platform is revolutionizing targeted genetic sequencing. Our mission is to change medicine by providing physicians, hospitals, and researchers with the tools to help patients treat and overcome major ...
CGx Testing is a preventative gene test that looks for specific inherited changes (mutations) in a person’s genetic make-up. Harmful mutations may increase a persons’ chance, or risk, of developing a disease such as cancer. These ...
based inFountain Valley, CALIFORNIA (USA)
Antech sets the standard for reference laboratory and imaging excellence. We are proud to have a world-class team of veterinary professionals putting you first with excellent customer service. At the heart of our company is our love for pets, their ...
Antech’s molecular diagnostics use and develop novel technologies that enable faster and more personalized diagnoses. With tests such as CADET® BRAF/PLUS and comprehensive PCR panels, we are the innovative leader in molecular ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
INOVIQ has developed a proprietary immunocytochemistry (ICC) assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial ...
based inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
based inBilthoven, NETHERLANDS
Bilthoven Biologicals produces various products such as polio, diphtheria tetanus polio combination vaccine (DT-IPV), tetanus vaccines and BCG for the treatment of bladder cancer. At BBio we are working on developing vaccines that give our world ...
BCG (Bacillus Calmette-Guérin) is known as a vaccine against tuberculosis. But BCG is also an effective medication used in the treatment of bladder cancer. Bilthoven Biologicals produces BCG for a third party ...
based inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the ...
based inRegensburg, GERMANY
numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that could not be addressed by single biomarker-based ...
Cancer is among the leading causes of death worldwide. Approximately 38 % of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013 – 2015 data1). ...
based inSan Diego, CALIFORNIA (USA)
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses ...
Bladder cancer is the 5th most common cancer in the western world, and 70%-80% of the patients are diagnosed with non-muscle invasive disease. There are estimated 400,000 to 800,000 active ...